Exact Mass: 465.2012
Exact Mass Matches: 465.2012
Found 500 metabolites which its exact mass value is equals to given mass value 465.2012
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cisapride
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity[1][2][3][4].
cisapride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity[1][2][3][4].
Biotripyrrin-a
Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247. These metabolites are recognized by an anti-bilirubin monoclonal antibody, 24G7, but are neg. in the diazo reaction. (PubMed ID 9836731 ). Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247
Biotripyrrin-b
Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247. These metabolites are recognized by an anti-bilirubin monoclonal antibody, 24G7, but are neg. in the diazo reaction. (PubMed ID 9836731 ). Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247
(Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]-N-methylsulfonylhept-5-enamide
Acalabrutinib
Benzylpenicilloyl G
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-leucine, TFA
2-{5-[(2,3,4,5,6-Pentamethylbenzyl)sulfanyl]-4-phenyl-4H-1,2,4-triazol-3-yl}-3-(2-pyridinyl)acrylonitrile
Ala Asp Phe Asn
Ala Asp Asn Phe
Ala Phe Asp Asn
Ala Phe Asn Asp
Ala Phe Gln Thr
Ala Phe Thr Gln
Ala Asn Asp Phe
Ala Asn Phe Asp
Ala Asn Val Tyr
Ala Asn Tyr Val
Ala Gln Phe Thr
Ala Gln Thr Phe
Ala Thr Phe Gln
Ala Thr Gln Phe
Ala Val Asn Tyr
Ala Val Tyr Asn
Ala Tyr Asn Val
Ala Tyr Val Asn
Cys Cys Ile Lys
Cys Cys Lys Ile
Cys Cys Lys Leu
Cys Cys Leu Lys
Cys Asp Lys Thr
Cys Asp Thr Lys
Cys Glu Lys Ser
Cys Glu Ser Lys
Cys Gly Met Arg
Cys Gly Arg Met
Cys Ile Cys Lys
Cys Ile Lys Cys
Cys Lys Cys Ile
Cys Lys Cys Leu
Cys Lys Asp Thr
Cys Lys Glu Ser
Cys Lys Ile Cys
Cys Lys Leu Cys
Cys Lys Ser Glu
Cys Lys Thr Asp
Cys Leu Cys Lys
Cys Leu Lys Cys
Cys Met Gly Arg
Cys Met Arg Gly
Cys Arg Gly Met
Cys Arg Met Gly
Cys Arg Ser Thr
Cys Arg Thr Ser
Cys Ser Glu Lys
Cys Ser Lys Glu
Cys Ser Arg Thr
Cys Ser Thr Arg
Cys Thr Asp Lys
Cys Thr Lys Asp
Cys Thr Arg Ser
Cys Thr Ser Arg
Asp Ala Phe Asn
Asp Ala Asn Phe
Asp Cys Lys Thr
Asp Cys Thr Lys
Asp Phe Ala Asn
Asp Phe Gly Lys
Asp Phe Gly Gln
Asp Phe Lys Gly
Asp Phe Asn Ala
Asp Phe Gln Gly
Asp Gly Phe Lys
Asp Gly Phe Gln
Asp Gly Lys Phe
Asp Gly Gln Phe
Asp Lys Cys Thr
Asp Lys Phe Gly
Asp Lys Gly Phe
Asp Lys Thr Cys
Asp Asn Ala Phe
Asp Asn Phe Ala
Asp Gln Phe Gly
Asp Gln Gly Phe
Asp Thr Cys Lys
Asp Thr Lys Cys
Glu Cys Lys Ser
Glu Cys Ser Lys
Glu Phe Gly Asn
Glu Phe Asn Gly
Glu Gly Phe Asn
Glu Gly Asn Phe
Glu Lys Cys Ser
Glu Lys Ser Cys
Glu Asn Phe Gly
Glu Asn Gly Phe
Glu Ser Cys Lys
Glu Ser Lys Cys
Phe Ala Asp Asn
Phe Ala Asn Asp
Phe Ala Gln Thr
Phe Ala Thr Gln
Phe Asp Ala Asn
Phe Asp Gly Lys
Phe Asp Gly Gln
Phe Asp Lys Gly
Phe Asp Asn Ala
Phe Asp Gln Gly
Phe Glu Gly Asn
Phe Glu Asn Gly
Phe Gly Asp Lys
Phe Gly Asp Gln
Phe Gly Glu Asn
Phe Gly Gly Trp
Phe Gly Lys Asp
Phe Gly Asn Glu
Phe Gly Gln Asp
Phe Gly Trp Gly
Phe Lys Asp Gly
Phe Lys Gly Asp
Phe Asn Ala Asp
Phe Asn Asp Ala
Phe Asn Glu Gly
Phe Asn Gly Glu
Phe Asn Ser Val
Phe Asn Val Ser
Phe Gln Ala Thr
Phe Gln Asp Gly
Phe Gln Gly Asp
Phe Gln Thr Ala
Phe Ser Asn Val
Phe Ser Val Asn
Phe Thr Ala Gln
Phe Thr Gln Ala
Phe Val Asn Ser
Phe Val Ser Asn
Phe Trp Gly Gly
Gly Cys Met Arg
Gly Cys Arg Met
Gly Asp Phe Lys
Gly Asp Phe Gln
Gly Asp Lys Phe
Gly Asp Gln Phe
Gly Glu Phe Asn
Gly Glu Asn Phe
Gly Phe Asp Lys
Gly Phe Asp Gln
Gly Phe Glu Asn
Gly Phe Gly Trp
Gly Phe Lys Asp
Gly Phe Asn Glu
Gly Phe Gln Asp
Gly Phe Trp Gly
Gly Gly Phe Trp
Gly Gly Trp Phe
Gly Ile Asn Tyr
Gly Ile Tyr Asn
Gly Lys Asp Phe
Gly Lys Phe Asp
Gly Lys Met Met
Gly Leu Asn Tyr
Gly Leu Tyr Asn
Gly Met Cys Arg
Gly Met Lys Met
Gly Met Met Lys
Gly Met Arg Cys
Gly Asn Glu Phe
Gly Asn Phe Glu
Gly Asn Ile Tyr
Gly Asn Leu Tyr
Gly Asn Tyr Ile
Gly Asn Tyr Leu
Gly Gln Asp Phe
Gly Gln Phe Asp
Gly Gln Val Tyr
Gly Gln Tyr Val
Gly Arg Cys Met
Gly Arg Met Cys
Gly Val Gln Tyr
Gly Val Tyr Gln
Gly Trp Phe Gly
Gly Trp Gly Phe
Gly Tyr Ile Asn
Gly Tyr Leu Asn
Gly Tyr Asn Ile
Gly Tyr Asn Leu
Gly Tyr Gln Val
Gly Tyr Val Gln
Ile Cys Cys Lys
Ile Cys Lys Cys
Ile Gly Asn Tyr
Ile Gly Tyr Asn
Ile Lys Cys Cys
Ile Asn Gly Tyr
Ile Asn Tyr Gly
Ile Tyr Gly Asn
Ile Tyr Asn Gly
Lys Cys Cys Ile
Lys Cys Cys Leu
Lys Cys Asp Thr
Lys Cys Glu Ser
Lys Cys Ile Cys
Lys Cys Leu Cys
Lys Cys Ser Glu
Lys Cys Thr Asp
Lys Asp Cys Thr
Lys Asp Phe Gly
Lys Asp Gly Phe
Lys Asp Thr Cys
Lys Glu Cys Ser
Lys Glu Ser Cys
Lys Phe Asp Gly
Lys Phe Gly Asp
Lys Gly Asp Phe
Lys Gly Phe Asp
Lys Gly Met Met
Lys Ile Cys Cys
Lys Leu Cys Cys
Lys Met Gly Met
Lys Met Met Gly
Lys Ser Cys Glu
Lys Ser Glu Cys
Lys Thr Cys Asp
Lys Thr Asp Cys
Leu Cys Cys Lys
Leu Cys Lys Cys
Leu Gly Asn Tyr
Leu Gly Tyr Asn
Leu Lys Cys Cys
Leu Asn Gly Tyr
Leu Asn Tyr Gly
Leu Tyr Gly Asn
Leu Tyr Asn Gly
Met Cys Gly Arg
Met Cys Arg Gly
Met Gly Cys Arg
Met Gly Lys Met
Met Gly Met Lys
Met Gly Arg Cys
Met Lys Gly Met
Met Lys Met Gly
Met Met Gly Lys
Met Met Lys Gly
Met Asn Thr Thr
Met Gln Ser Thr
Met Gln Thr Ser
Met Arg Cys Gly
Met Arg Gly Cys
Met Ser Gln Thr
Met Ser Thr Gln
Met Thr Asn Thr
Met Thr Gln Ser
Met Thr Ser Gln
Met Thr Thr Asn
Asn Ala Asp Phe
Asn Ala Phe Asp
Asn Ala Val Tyr
Asn Ala Tyr Val
Asn Asp Ala Phe
Asn Asp Phe Ala
Asn Glu Phe Gly
Asn Glu Gly Phe
Asn Phe Ala Asp
Asn Phe Asp Ala
Asn Phe Glu Gly
Asn Phe Gly Glu
Asn Phe Ser Val
Asn Phe Val Ser
Asn Gly Glu Phe
Asn Gly Phe Glu
Asn Gly Ile Tyr
Asn Gly Leu Tyr
Asn Gly Tyr Ile
Asn Gly Tyr Leu
Asn Ile Gly Tyr
Asn Ile Tyr Gly
Asn Leu Gly Tyr
Asn Leu Tyr Gly
Asn Met Thr Thr
Asn Ser Phe Val
Asn Ser Val Phe
Asn Thr Met Thr
Asn Thr Thr Met
Asn Val Ala Tyr
Asn Val Phe Ser
Asn Val Ser Phe
Asn Val Tyr Ala
Asn Tyr Ala Val
Asn Tyr Gly Ile
Asn Tyr Gly Leu
Asn Tyr Ile Gly
Asn Tyr Leu Gly
Asn Tyr Val Ala
Gln Ala Phe Thr
Gln Ala Thr Phe
Gln Asp Phe Gly
Gln Asp Gly Phe
Gln Phe Ala Thr
Gln Phe Asp Gly
Gln Phe Gly Asp
Gln Phe Thr Ala
Gln Gly Asp Phe
Gln Gly Phe Asp
Gln Gly Val Tyr
Gln Gly Tyr Val
Gln Met Ser Thr
Gln Met Thr Ser
Gln Ser Met Thr
Gln Ser Thr Met
Gln Thr Ala Phe
Gln Thr Phe Ala
Gln Thr Met Ser
Gln Thr Ser Met
Gln Val Gly Tyr
Gln Val Tyr Gly
Arg Cys Gly Met
Arg Cys Met Gly
Arg Cys Ser Thr
Arg Cys Thr Ser
Arg Gly Cys Met
Arg Gly Met Cys
Arg Met Cys Gly
Arg Met Gly Cys
Arg Ser Cys Thr
Arg Ser Thr Cys
Arg Thr Cys Ser
Arg Thr Ser Cys
Ser Cys Glu Lys
Ser Cys Lys Glu
Ser Cys Arg Thr
Ser Cys Thr Arg
Ser Glu Cys Lys
Ser Glu Lys Cys
Ser Lys Cys Glu
Ser Lys Glu Cys
Ser Met Gln Thr
Ser Met Thr Gln
Ser Gln Met Thr
Ser Gln Thr Met
Ser Arg Cys Thr
Ser Arg Thr Cys
Ser Ser Ser Trp
Ser Ser Trp Ser
Ser Thr Cys Arg
Ser Thr Met Gln
Ser Thr Gln Met
Ser Thr Arg Cys
Ser Trp Ser Ser
Thr Cys Asp Lys
Thr Cys Lys Asp
Thr Cys Arg Ser
Thr Cys Ser Arg
Thr Asp Cys Lys
Thr Asp Lys Cys
Thr Lys Cys Asp
Thr Lys Asp Cys
Thr Met Asn Thr
Thr Met Gln Ser
Thr Met Ser Gln
Thr Met Thr Asn
Thr Asn Met Thr
Thr Asn Thr Met
Thr Gln Met Ser
Thr Gln Ser Met
Thr Arg Cys Ser
Thr Arg Ser Cys
Thr Ser Cys Arg
Thr Ser Met Gln
Thr Ser Gln Met
Thr Ser Arg Cys
Thr Thr Met Asn
Thr Thr Asn Met
Trp Phe Gly Gly
Trp Gly Phe Gly
Trp Gly Gly Phe
Trp Ser Ser Ser
Tyr Leu Gly Asn
Sulprostone
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D008600 - Menstruation-Inducing Agents D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C78568 - Prostaglandin Analogue
Sarpogrelate Hydrochloride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].
N-(3,5-DICHLORO-2-HYDROXY-4-METHYLPHENYL)-2-(2,4-DI-TERT-PENTYLPHENOXY)-ACETAMIDE
TERT-BUTYL 5-((4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL)SULFONYL)-1H-INDOLE-1-CARBOXYLATE
4-METHOXYPHENYL 2-AMINO-3,6-DI-O-BENZYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
Acalabrutinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-Pyrrolidinone, 1-(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-4-(2-methylpropyl)-, (4R)-
(1S,2R)-(-)-2-AMINOCYCLOHEX-3-ENECARBOXYLICACIDHYDROCHLORIDE
CID 24906286
Bevonium metilsulfate
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
Tert-Butyl 4-({[4-(But-2-Yn-1-Ylamino)phenyl]sulfonyl}methyl)-4-[(Hydroxyamino)carbonyl]piperidine-1-Carboxylate
[[(E)-5-[(1S,2S,8aR)-2-hydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoxy]-oxidophosphoryl] phosphate
[(3S)-3-acetamido-5-[[(2S,3S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-2-carboxy-3,6-dihydro-2H-pyran-3-yl]amino]-5-oxopentyl]-(diaminomethylidene)-methylazanium
(2R)-2-amino-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[(1R,2R)-2-hydroxy-1-[[(2S,4R)-4-propylpyrrolidine-2-carbonyl]amino]propyl]oxan-2-yl]sulfanylpropanoic acid
(Z,Z)-2-[[3-(2-carboxyethyl)-5-[(4-ethenyl-1,5-dihydro-3-methyl-5-oxo-2H-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methylene]-2,5-dihydro-4-methyl-5-oxo-1H-Pyrrole-3-propanoate
N-[2-(tert-butylamino)-2-oxo-1-thiophen-2-ylethyl]-N-(2-oxolanylmethyl)-5-phenyl-1H-pyrrole-2-carboxamide
5-[[2-[4-[1-(1,3-Dioxo-2-indenylidene)ethyl]-1-piperazinyl]ethylamino]methylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(thiophen-2-ylmethyl)amino]-2-(2-furanyl)-N-(3-methylbutyl)acetamide
2-[[5-[(2,6-Dimethylphenoxy)methyl]-4-ethyl-1,2,4-triazol-3-yl]thio]-1-(4-phenyl-1-piperazinyl)ethanone
(2E)-5-[(1S,2S,4aR,8aR)-2-hydroxy-2,5,5,8a-tetramethyldecahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl diphosphate
(2E)-5-[(1R,2R,4aS,8aS)-1-hydroxy-2,5,5,8a-tetramethyldecahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl diphosphate
[(1S)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-cyclopropylmethanone
[(1R)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-cyclopropylmethanone
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2R,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2S,3R)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(2R,3R)-4-[(2-chlorophenyl)methyl-[(2R)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-1-methyl-4-imidazolesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
1-[(2S,3S)-4-[(2-chlorophenyl)methyl-[(2S)-1-hydroxypropan-2-yl]amino]-2-methoxy-3-methylbutyl]-3-(4-fluorophenyl)-1-methylurea
1-[(1S)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
1-[(1R)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
[(1R)-2-[(4-chlorophenyl)methyl]-1-(cyclopropylmethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)-1-(N,N-dimethylglycyl)piperidine-4-carboxamide
(1E,3E)-5-(3,3-dimethyloxiran-2-yl)-3-methylhexa-1,3-dienyl-quinolinone B
(3R,4R)-4,5-dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-[(E)-2-[(2S,5S)-2-methyl-5-prop-1-en-2-yloxolan-2-yl]ethenyl]-1,3-dihydroquinolin-2-one
Propulsid
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity[1][2][3][4].
(2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid
YM-58790
YM-58790 is a potent antagonist of mAChR. YM-58790 binds M1, M2, M3 with Ki values of 28 nM, 260 nM, and 15 nM. YM-58790 exhibits potent inhibitory activity on bladder pressuer in reflexly-evoked rhythmic contraction in rats[1].